Vincerx Pharma Past Earnings Performance
Past criteria checks 0/6
Vincerx Pharma's earnings have been declining at an average annual rate of -18.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-18.8%
Earnings growth rate
-0.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -296.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Revenue & Expenses Breakdown
How Vincerx Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -27 | 12 | 16 |
| 30 Jun 24 | 0 | -28 | 12 | 18 |
| 31 Mar 24 | 0 | -38 | 12 | 23 |
| 31 Dec 23 | 0 | -40 | 14 | 29 |
| 30 Sep 23 | 0 | -46 | 16 | 34 |
| 30 Jun 23 | 0 | -54 | 17 | 39 |
| 31 Mar 23 | 0 | -61 | 18 | 45 |
| 31 Dec 22 | 0 | -63 | 19 | 50 |
| 30 Sep 22 | 0 | -58 | 20 | 53 |
| 30 Jun 22 | 0 | -66 | 21 | 54 |
| 31 Mar 22 | 0 | -49 | 23 | 51 |
| 31 Dec 21 | 0 | -39 | 23 | 40 |
| 30 Sep 21 | 0 | -49 | 20 | 30 |
| 30 Jun 21 | 0 | -25 | 15 | 18 |
| 31 Mar 21 | 0 | -23 | 8 | 7 |
| 31 Dec 20 | 0 | -17 | 4 | 2 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
Quality Earnings: VINC is currently unprofitable.
Growing Profit Margin: VINC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VINC is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.
Accelerating Growth: Unable to compare VINC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VINC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: VINC has a negative Return on Equity (-296.77%), as it is currently unprofitable.